MX367478B - Tratamiento de enfermedades colestasicas intrahepaticas. - Google Patents

Tratamiento de enfermedades colestasicas intrahepaticas.

Info

Publication number
MX367478B
MX367478B MX2016012203A MX2016012203A MX367478B MX 367478 B MX367478 B MX 367478B MX 2016012203 A MX2016012203 A MX 2016012203A MX 2016012203 A MX2016012203 A MX 2016012203A MX 367478 B MX367478 B MX 367478B
Authority
MX
Mexico
Prior art keywords
treatment
intrahepatic
diseases
cholestic
mbx
Prior art date
Application number
MX2016012203A
Other languages
English (en)
Spanish (es)
Other versions
MX2016012203A (es
Inventor
A Mcwherter Charles
Boudes Pol
Original Assignee
Cymaby Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymaby Therapeutics Inc filed Critical Cymaby Therapeutics Inc
Publication of MX2016012203A publication Critical patent/MX2016012203A/es
Publication of MX367478B publication Critical patent/MX367478B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
MX2016012203A 2014-03-20 2015-03-19 Tratamiento de enfermedades colestasicas intrahepaticas. MX367478B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461968037P 2014-03-20 2014-03-20
PCT/US2015/021502 WO2015143178A1 (en) 2014-03-20 2015-03-19 Treatment of intrahepatic cholestatic diseases

Publications (2)

Publication Number Publication Date
MX2016012203A MX2016012203A (es) 2017-01-19
MX367478B true MX367478B (es) 2019-08-23

Family

ID=52808186

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012203A MX367478B (es) 2014-03-20 2015-03-19 Tratamiento de enfermedades colestasicas intrahepaticas.

Country Status (32)

Country Link
US (5) US9486428B2 (2)
EP (1) EP3119384B1 (2)
JP (1) JP6568577B2 (2)
KR (1) KR102000332B1 (2)
CN (1) CN106102734B (2)
AU (1) AU2015231232B2 (2)
BR (1) BR112016020260A8 (2)
CA (1) CA2941401C (2)
CL (1) CL2016002338A1 (2)
CY (1) CY1120927T1 (2)
DK (1) DK3119384T3 (2)
EA (1) EA032358B1 (2)
ES (1) ES2701094T3 (2)
FI (1) FIC20253004I1 (2)
FR (1) FR25C1031I2 (2)
HR (1) HRP20181914T1 (2)
HU (2) HUE041733T2 (2)
IL (1) IL247920B (2)
LT (2) LT3119384T (2)
MX (1) MX367478B (2)
NL (1) NL301338I2 (2)
NO (1) NO2025035I1 (2)
NZ (1) NZ724057A (2)
PH (1) PH12016501769B1 (2)
PL (1) PL3119384T3 (2)
PT (1) PT3119384T (2)
RS (1) RS57970B1 (2)
SI (1) SI3119384T1 (2)
SM (1) SMT201800690T1 (2)
UA (1) UA120756C2 (2)
WO (1) WO2015143178A1 (2)
ZA (1) ZA201606043B (2)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5694941B2 (ja) 2008-10-17 2015-04-01 シーマベイ セラピューティクス，インコーポレイティド 小型高密度ｌｄｌ粒子を減少させる方法
US10272058B2 (en) * 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
BR112016023269A8 (pt) 2014-04-11 2021-06-29 Cymabay Therapeutics Inc uso de ácido (r)-2-(4-((2-etóxi-3-(4-(trifluormetil)fenóxi)propil)-tio)-2-metilfenóxi)-acético ou sal do mesmo na fabricação de um medicamento para tratar doença hepática gordurosa não alcoólica ou esteato-hepatite não alcoólica
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
SMT202200171T1 (it) * 2017-09-26 2022-05-12 Cymabay Therapeutics Inc Trattamento del prurito colestatico con seladelpar
CA3118965A1 (en) * 2018-11-16 2020-05-22 Cymabay Therapeutics, Inc. Treatment of obesity and its complications
CA3148602A1 (en) 2019-08-02 2021-02-11 Acelot, Inc. Small molecule drugs and related methods for treatment of diseases related to tdp-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation
US20210145775A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of intestinal barrier dysfunction and associated diseases
US20210145774A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of alcoholic liver disease
FI4225291T3 (fi) 2021-02-01 2024-06-03 Cymabay Therapeutics Inc Kolangiopatioiden hoito seladelpaarilla

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
AU5359496A (en) 1995-03-06 1996-09-23 Isis Pharmaceuticals, Inc. Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
ATE267207T1 (de) 1996-02-14 2004-06-15 Isis Pharmaceuticals Inc Kohlenhydratmodifizierte luckenhafte oligonukleotide
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7981915B2 (en) * 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
EP1667964B1 (en) 2003-09-19 2009-07-22 Janssen Pharmaceutica N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
US7932268B2 (en) 2004-03-05 2011-04-26 The Trustees Of The University Of Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
JP5694941B2 (ja) 2008-10-17 2015-04-01 シーマベイ セラピューティクス，インコーポレイティド 小型高密度ｌｄｌ粒子を減少させる方法
MA34097B1 (fr) 2010-03-30 2013-03-05 Novartis Ag Utilisations d'inhibiteurs de dgat1
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
HK1224186A1 (zh) 2013-11-20 2017-08-18 Cymabay Therapeutics, Inc. 纯阖家族型高胆固醇血症的治疗
US20160279085A1 (en) 2013-11-20 2016-09-29 Cymabay Therapeutics, Inc. Treatment of Severe Hyperlipidemia
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
BR112016023269A8 (pt) 2014-04-11 2021-06-29 Cymabay Therapeutics Inc uso de ácido (r)-2-(4-((2-etóxi-3-(4-(trifluormetil)fenóxi)propil)-tio)-2-metilfenóxi)-acético ou sal do mesmo na fabricação de um medicamento para tratar doença hepática gordurosa não alcoólica ou esteato-hepatite não alcoólica
EA201790091A1 (ru) 2014-06-26 2017-07-31 Саймабэй Терапьютикс, Инк. Лечение тяжелой гипертриглицеридемии
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
SMT202200171T1 (it) 2017-09-26 2022-05-12 Cymabay Therapeutics Inc Trattamento del prurito colestatico con seladelpar
CA3118965A1 (en) 2018-11-16 2020-05-22 Cymabay Therapeutics, Inc. Treatment of obesity and its complications
WO2020102337A1 (en) 2018-11-16 2020-05-22 Cymabay Therapeutics, Inc. Combination treatment of nafld and nash

Also Published As

Publication number Publication date
CA2941401A1 (en) 2015-09-24
WO2015143178A1 (en) 2015-09-24
PT3119384T (pt) 2018-12-12
HUE041733T2 (hu) 2019-05-28
US9486428B2 (en) 2016-11-08
SMT201800690T1 (it) 2019-01-11
IL247920B (en) 2019-03-31
KR20160125424A (ko) 2016-10-31
FIC20253004I1 (fi) 2025-07-31
ES2701094T3 (es) 2019-02-20
UA120756C2 (uk) 2020-02-10
LTPA2025529I1 (2) 2025-08-25
US11406611B2 (en) 2022-08-09
PH12016501769A1 (en) 2017-01-09
US20190192459A1 (en) 2019-06-27
US10220011B2 (en) 2019-03-05
CA2941401C (en) 2019-06-11
CY1120927T1 (el) 2019-12-11
MX2016012203A (es) 2017-01-19
EA032358B1 (ru) 2019-05-31
CN106102734A (zh) 2016-11-09
DK3119384T3 (en) 2018-12-03
US10828273B2 (en) 2020-11-10
US20180036268A1 (en) 2018-02-08
US20170014363A1 (en) 2017-01-19
HUS2500033I1 (hu) 2025-09-28
SI3119384T1 (sl) 2018-12-31
ZA201606043B (en) 2018-05-30
NZ724057A (en) 2018-09-28
CN106102734B (zh) 2019-05-14
JP2017508817A (ja) 2017-03-30
FR25C1031I1 (fr) 2025-09-26
RS57970B1 (sr) 2019-01-31
US20150265560A1 (en) 2015-09-24
KR102000332B1 (ko) 2019-07-15
NO2025035I1 (no) 2025-08-01
CL2016002338A1 (es) 2017-04-21
LT3119384T (lt) 2018-11-26
BR112016020260A8 (pt) 2021-06-29
FR25C1031I2 (fr) 2026-03-27
PH12016501769B1 (en) 2017-01-09
NL301338I2 (nl) 2025-09-11
EP3119384B1 (en) 2018-09-12
HRP20181914T1 (hr) 2019-01-11
EP3119384A1 (en) 2017-01-25
EA201691887A1 (ru) 2017-03-31
JP6568577B2 (ja) 2019-08-28
BR112016020260A2 (pt) 2017-08-15
AU2015231232A1 (en) 2016-09-22
AU2015231232B2 (en) 2018-08-02
US20210023031A1 (en) 2021-01-28
PL3119384T3 (pl) 2019-03-29
US9808436B2 (en) 2017-11-07

Similar Documents

Publication Publication Date Title
MX367478B (es) Tratamiento de enfermedades colestasicas intrahepaticas.
MX2020007273A (es) Tratamiento del prurito colestasico.
IL283561B (en) Methods for treating ocular diseases
MX369921B (es) Tratamiento de la hgna y ehna.
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
IL249065A0 (en) Combination therapies for the treatment of cancer
DK3450553T3 (da) Mrna-terapi til behandling af øjensygdomme
PL3212174T3 (pl) Sposoby leczenia zakażeń wirusem filoviridae
ECSP17015977A (es) Terapia de combinacion
LT3556775T (lt) Anti-lag-3 antikūnai, skirti hematologinių piktybinių susirgimų gydymui
DK3134530T3 (da) Behandling af hyperbilirubinæmi
EP3448263A4 (en) ELECTROTHERAPEUTIC TREATMENT
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
EP3186010A4 (en) IMMERSIVE SHOWER HEAD
HUE047542T2 (hu) A rák kombinált kezelése
MX2018014915A (es) Tratamiento de enfermedades colestasicas intrahepaticas.
HUE053443T2 (hu) Heteroaril vegyületek szembetegségek kezelésére
FI20145484A7 (fi) Anodiliejun hydrometallurginen käsittely
DK2897382T3 (da) Forbedring af binaural kilde
IL257764B (en) Methods for treatment of diseases
SI3188599T1 (sl) Zdravljenje na osnovi anamorelina
DK3151814T3 (da) Behandling af en hudlæsion
IL246558A0 (en) Novel methods for treating cancer
PL3160913T3 (pl) Sposób oczyszczania osadu biologicznego
DK3182980T3 (da) Behandling af glykosyleringsmangelsygdomme

Legal Events

Date Code Title Description
FG Grant or registration